Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers

Tik-Hung Tsoi, Chi-Fai Chan, Wai-Lun Chan, Ka-Fung Chiu, Wing-Tak Wong, Chi-Fai Ng, Ka-Leung Wong, Tik-Hung Tsoi, Chi-Fai Chan, Wai-Lun Chan, Ka-Fung Chiu, Wing-Tak Wong, Chi-Fai Ng, Ka-Leung Wong

Abstract

Current screening methods towards prostate cancer (PCa) are not without limitations. Research work has been on-going to assess if there are other better tests suitable for primary or secondary screening of PCa to supplement the serum prostate specific antigen (PSA) test, which fails to work accurately in a grey zone of 4-10ng/ml. In this pilot study, the potential roles of urinary polyamines as prostate cancer biomarkers were evaluated. PCa, benign prostatic hyperplasia (BPH) patients and healthy controls (HC) showing PSA>4.0ng/ml were enrolled in the study. Their urine samples were obtained, and the urinary levels of putrescine (Put), spermidine (Spd) and spermine (Spm) were determined by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometer (UPLC-MS/MS). Receiver operating characteristics (ROC) curve and Student's t-test were used to evaluate their diagnostic accuracies. Among the three biogenic polyamines, Spm had demonstrated a good diagnostic performance when comparing their levels in PCa patients with BPH patients (1.47 in PCa vs 5.87 in BPH; p<0.0001). Results are in accordance with transrectal ultrasound prostatic biopsy (TRUSPB) results, with an area under curve (AUC) value of 0.83±0.03. Therefore urinary Spm shows potential to serve as a novel PCa diagnostic biomarker, which in turn can help to address the limited sensitivity and specificity problem of serum PSA test.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Overlaid UPLC-MS/MS SRM chromatograms of…
Fig 1. Overlaid UPLC-MS/MS SRM chromatograms of 1000 ppb mixed polyamines standard (0–10 mins being shown).
Put (Black peak, tR = 4.3 min), Put-d8 (Pink peak, tR = 4.3 min), Spd (Blue peak, tR = 6.6 min), Spd-d8 (Red peak, tR = 6.6 min), Spm (Yellow peak, tR = 7.9 min) and Spm-d8 (Green peak, tR = 7.9 min).
Fig 2. Distribution of (A) normalized Put,…
Fig 2. Distribution of (A) normalized Put, (B) normalized Spd, (C) normalized Spm values in PCa, BPH and HC.
The black bar in the figures indicates the mean value of each subset while the error bar indicates the corresponding SEM.
Fig 3. Receiver operating characteristic analysis for…
Fig 3. Receiver operating characteristic analysis for normalized Put, Spd and Spm values.
Fig 4. Polyamine metabolic pathway (focusing on…
Fig 4. Polyamine metabolic pathway (focusing on Put, Spd and Spm only).

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. 10.3322/caac.21254
    1. Bhavsar T, McCue P, Birbe R. Molecular diagnosis of prostate cancer: are we up to age? Seminars in oncology. 2013;40(3):259–75. 10.1053/j.seminoncol.2013.04.002
    1. Schroder FH, Kruger AB, Rietbergen J, Kranse R. Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer. JNCI. 1998;90(23):1817–23.
    1. Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, et al. The present and future of prostate cancer urine biomarkers. INT J MOL SCI. 2013;14(6):12620–49. 10.3390/ijms140612620
    1. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815–6.
    1. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999;54(3):517–22.
    1. Van Cangh PJ, De Nayer P, De Vischer L, Sauvage P, Tombal B, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology. 1996;48(6):67–70.
    1. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650–5. 10.1016/j.juro.2010.12.032
    1. Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol. 2014;46(4):711–7. 10.1007/s11255-013-0582-0
    1. Wu CL, Carter HB, Naqibuddin M, Fleisher LA. Effect of local anesthetics on patient recovery after transrectal biopsy. Urology. 2001;57(5):925–9.
    1. Chan ES, Lo KL, Ng CF, Hou SM, Yip SK. Randomized controlled trial of antibiotic prophylaxis regimens for transrectal ultrasound- guided prostate biopsy. Chin Med J. 2012;125(14):2432–5.
    1. Wagenlehner FM, Van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013;63(3):521–7. 10.1016/j.eururo.2012.06.003
    1. Downes MR, Byrne JC, Pennington SR, Dunn MJ, Fitzpatrick JM, et al. Urinary markers for prostate cancer. BJU Int.2007;99(2):263–8.
    1. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1): 12–9. 10.1038/pcan.2009.31
    1. Wilkosz J, Bryś M, Różański W. Urine markers and prostate cancers. Cent European J Urol. 2011;64(1),9–14. 10.5173/ceju.2011.01.art2
    1. Russell DH. Increased polyamine concentrations in the urine of human cancer patients. Nat New Biol. 1971;233(39):144–5.
    1. Lee SH, Yang YJ, Kim KM, Chung BC. Altered urinary profiles of polyamines and endogenous steroids in patients with benign cervical disease and cervical cancer. Cancer Lett. 2003;201(2):121–31.
    1. Löser C, Fölsch UR, Paprotny C, Creutzfeldt W. Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Cancer. 1990;65(4):958–66.
    1. Levêque J, Foucher F, Bansard JY, Havouis R, Grall JY, Moulinoux JP. Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat. 2000;60(2):99–105.
    1. Schipper RG, Romijn JC, Cuijpers VMJI, Verhofstad AAJ. Polyamines and prostatic cancer. Biochem Soc Trans. 2003;31(2):375–80.
    1. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000;10(3):153–9.
    1. Bonsnes RW, Taussky HH. On the colorimetric determination of creatinine by the Jaffé reaction. J Biol Chem. 1945;158(3):581–91.
    1. Häkkinen MR, Roine A, Auriola S, Tuokko A, Veskimäe E, Keinänen TA, et al. Analysis of free, mono- and diacetylated polyamines from human urine by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;941:81–9. 10.1016/j.jchromb.2013.10.009
    1. Jung K. Enzyme activities in urine: how should we express their excretion? A critical literature review. Eur J Clin Chem Clin Biochem. 1991;29:725–9.
    1. Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res. 2011;30(1):1.
    1. Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med. 2003;7(2):113–26.
    1. Bachrach U. Polyamines and cancer: Minireview article. Amino Acids. 2004;26(4): 307–9.
    1. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, et al. N1,N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers. Clin Cancer Res. 2005;11(8):2986–90.
    1. Liu R, Li Q, Ma R, Lin X, Xu H, Bi K. Determination of polyamine metabolome in plasma and urine by ultrahigh performance liquid chromatography-tandem mass spectrometry method: Application to identify potential markers for human hepatic cancer. Anal Chim Acta. 2013;791:36–45. 10.1016/j.aca.2013.06.044
    1. Fair WR, Wehner N, Brorsson U. Urinary polyamine levels in the diagnosis of carcinoma of the prostate. J Urol. 1975;114(1):88–92.
    1. Horn Y, Beal SL, Walach N, Lubich WP, Spigel L, Marton LJ. Relationship of urinary polyamines to tumor activity and tumor volume in patients. Cancer Res. 1984;44(10):4675–8.
    1. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003;50(5): 944–54.
    1. Giskeødegård GF, Bertilsson H, Selnæs KM, Wright AJ, Bathen TF, Viset T, et al. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 2013;8(4):e62375 10.1371/journal.pone.0062375
    1. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate. 2008;68(6), 620–8. 10.1002/pros.20727
    1. Cheng LL, Wu CL, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Letters. 2001;494(1–2):112–6.
    1. Battaglia V, Shields CD, Murray-Stewart T, Casero RA Jr. Polyamine catabolism in carcinogenesis: potential targets for chemotherapy and chemoprevention. Amino Acids. 2014;46(3):511–9. 10.1007/s00726-013-1529-6
    1. Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J. 2009;421(3):323–38. 10.1042/BJ20090598
    1. Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, Kowalski J, et al. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate. 2008;68(7):766–72. 10.1002/pros.20735
    1. Hiramatsu K, Sugimoto M, Kamei S, Hoshino M, Kinoshita K, Iwasaki K, et al. Diagnostic and prognostic usefulness of N1, N8-diacetylspermidine and N1, N12-diacetylspermine in urine as novel markers of malignancy. J Cancer Res Clin Oncol. 1997;123(10):539–45.
    1. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008;64(1):10–19.
    1. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13(3):939–43.
    1. Li J, Veltri RW, Yuan Z, Christudass CS, Mandecki W. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer. PLoS One. 2015;10(4):e0122249 10.1371/journal.pone.0122249
    1. Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G, et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10ng/ml. PLoS One 2013;8(7):e67687 10.1371/journal.pone.0067687
    1. Vargas AJ, Ashbeck EL, Thomson CA, Gerner EW, Thompson PA. Dietary polyamine intake and polyamines measured in urine. Nutr Cancer. 2014;66(7): 1144–53. 10.1080/01635581.2014.949801

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться